CD200 expression is a feature of solid pseudopapillary neoplasms of the pancreas

Abstract

CD200 has been recently indicated as a robust marker of well-differentiated neuroendocrine neoplasms. Here, we evaluate its role in differential diagnosis of solid pancreatic neoplasms. We immunostained for CD200 22 solid pseudopapillary neoplasms (SPNs), 8 acinar carcinomas (ACs), 2 pancreatoblastomas (PBs), 138 neuroendocrine tumors (PanNETs), and 48 ductal adenocarcinomas. All SPNs showed strong cytoplasmic and membranous staining for CD200, while only one case of AC had focal positivity. The two PBs showed focal CD200 positivity, mainly located in squamoid nests. The vast majority of PanNETs (96%) showed strong cytoplasmic and membranous staining for CD200, whereas all PDACs were negative. As both PanNETs and SPNs express CD200, it has no role in the differential diagnosis between these two entities.

Pancreatic Solid Pseudopapillary Neoplasm: Key Pathologic and Genetic Features

“…Solid pseudopapillary neoplasms have been found to be positive for glutamine synthase, a-methylacyl-CoA racemase (P504s; Figure 8, C), transcription factor E3 (TFE3; Figure 8, D), SOX11, lymphoid enhancer-binding factor 1 (LEF1), androgen receptor (AR), fused in sarcoma (FUS), WNT inhibitor factor-1 (WIF-1), CD138, and CD200. [28][29][30][31][32][33][34] Immunoreactivity for cytokeratins, synaptophysin, and CD56 can be observed in 30% to 70% of cases, whereas chromogranin A is negative. 1 Up to 50% of SPNs can be positive for CD117, but KIT mutation has not been demonstrated.…”

Prognostic Value of CD200 Expression and Soluble CTLA-4 Concentrations in Intermediate and High-Risk Myelodysplastic Syndrome Patients

“…The over-expression of CD200 is linked with expansion of suppressive Treg cells and plays a vital role in the progression of multiple myeloma (Aref et al, 2017). So far, Several reports concluded that CD200 expression is also associated with the progression of various solid cancers, such as bladder cancer, lung cancer, breast cancer prostate carcinoma, cutaneous squamous cell carcinoma and acute myeloid leukemia (Kretz-Rommel et al, 2007;Lawlor et al, 2019;Aref et al 2020).…”

CD117 Is a Specific Marker of Intraductal Papillary Mucinous Neoplasms (IPMN) of the Pancreas, Oncocytic Subtype

“…Immunohistochemical analysis (IHC) was performed as already described [ 28 , 29 , 30 ]. Briefly, four μm formalin-fixed and paraffin-embedded sections were immunostained with CD117 antibody (rabbit polyclonal, 1:100 dilution, Dako/USA).…”